This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neurology	Claudin 5 (CLDN5)	<p>Mouse studies suggest blocking CLDN5 in the brain could help relieve brain edema and help treat traumatic brain injury. In mice, systemic delivery of <i>Cldn5</i>-targeting small interfering RNA one hour postinjury increased water permeability across the blood brain barrier, decreased edema and increased recovery of cognitive function compared with delivery of nontargeting siRNA. Ongoing studies include evaluating the safety of delivering the <i>Cldn5</i>-targeting siRNA in a nonhuman primate model. Avena Therapeutics Ltd. is developing a platform technology to modulate neuronal barrier permeability.</p> <p>SciBX 5(22); doi:10.1038/scibx.2012.578 Published online May 31, 2012</p>	Patent applications filed covering methods for modulating neuronal barrier; available for licensing from Avena Therapeutics	<p>Campbell, M. <i>et al. Nat. Commun.</i>; published online May 22, 2012; doi:10.1038/ncomms1852 Contact: Matthew Campbell, Trinity College Dublin, Dublin, Ireland e-mail: matthew.campbell@tcd.ie</p>